Acceptance and Commitment Therapy for HIV+ Hazardous Drinkers
Launched by SYRACUSE UNIVERSITY · Oct 16, 2024
Trial Information
Current as of August 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a type of therapy called Acceptance and Commitment Therapy (ACT) to help people living with HIV who drink alcohol at unhealthy levels. The goal is to see if ACT can reduce alcohol use and improve mental health symptoms like depression and anxiety. Participants will be randomly assigned to either the ACT program or another therapy known as Brief Intervention (BI). The study will follow participants over several months to assess changes in their drinking and overall well-being.
To be eligible for this trial, you must be an adult (18 years or older) living with HIV and report drinking at unhealthy levels based on a specific questionnaire. You should also be currently receiving treatment for HIV and able to read at an 8th-grade level. However, if you have severe depression or anxiety, you won’t be able to participate, but you will receive referrals for mental health support. Participants can expect to take part in six phone sessions over about seven weeks, and they will have their alcohol use and mental health tracked at various points during and after the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Living with HIV
- • Drink at unhealthy levels based on self-reported answers to the AUDIT-C, referencing drinking over the previous 3 months \[score of ≥4 (men) or ≥3 (women) will be used to identify eligible participants\]
- • on HIV treatment and are
- • 18 years or older.
- • Read at an 8th grade level
- • Can provide a physical address
- • Able to provide informed consent
- Exclusion Criteria:
- • Anyone with a score = 12 on the AUDIT-C will be excluded.
- • Anyone with a score ≥20 on the PHQ-9, indicative of severe depression, will be excluded.
- • Anyone with a score of ≥15 on the GAD-7, indicative of severe anxiety, will be excluded.
- • Referrals for mental health treatment will be given to all participants who screen out.
About Syracuse University
Syracuse University is a prestigious research institution dedicated to advancing knowledge and innovation across various fields, including health sciences and medicine. As a clinical trial sponsor, Syracuse University harnesses its academic expertise and state-of-the-art facilities to conduct rigorous research aimed at improving patient outcomes and addressing critical health challenges. With a commitment to ethical practices and collaboration, Syracuse University fosters partnerships with healthcare professionals, industry leaders, and community stakeholders to drive impactful clinical studies that contribute to the advancement of evidence-based practices and the betterment of public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Syracuse, New York, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported